Impact of Treatment Prior to Allogeneic Transplantation of Hematopoietic Stem Cells in Patients with Myelodysplastic Syndrome: Results of the Latin American Bone Marrow Transplant Registry.

Autor: Duarte FB; Clinical Hospital, Department of Surgery, Federal University of Ceara, Fortaleza, Brazil., Moura ATG; Hematology Research Laboratory, Federal University of Ceara, Fortaleza, Brazil. Electronic address: thawanny.anna@gmail.com., Funke VAM; Bone Marrow Transplant, Federal University of Parana, Curitiba, Brazil., Colturato VAR; Bone Marrow Transplant, Amaral Carvalho Foundation, Jaú, Brazil., Hamerschlak N; Bone Marrow Transplant, Hospital Israelita Albert Einstein, São Paulo, Brazil., Vilela NC; Brazilian Cooperative Group of MDS in Pediatrics, Barretos Children's and Youth Cancer Hospital, São Paulo, Brazil., Lopes LF; Brazilian Cooperative Group of MDS in Pediatrics, Barretos Children's and Youth Cancer Hospital, São Paulo, Brazil., de Almeida Macedo MCM; Bone Marrow Transplant, Brazilian Institute of Cancer Control, São Paulo, Brazil., Vigorito AC; Hemocentro TCTH, State University of Campinas, Campinas, Brazil., de Almeida Soares RD; Bone Marrow Transplant, Natal Hospital Center, Natal, Brazil., Paz A; Bone Marrow Transplant, Clinical Hospital of Porto Alegre, Porto Alegre, Brazil., Stevenazzi M; Bone Marrow Transplant, Uruguayan Clinics Hospital, Montevideo, Uruguay., Diaz L; Bone Marrow Transplant, Uruguayan Clinics Hospital, Montevideo, Uruguay., Neto AEH; Bone Marrow Transplant, University Hospital of Juiz de Fora, Juiz de Fora, Brazil., Bettarello G; Bone Marrow Transplant, Pietro Albuquerque ICDF, São Paulo, Brazil., de Gusmão BM; Bone Marrow Transplant, Hospital São José, São Paulo, Brazil., Salvino MA; Bone Marrow Transplant Center, Hospital Universitário Prof. Edgard Santos, Salvador, Brazil., Calixto RF; Bone Marrow Transplant, Real Hospital Português de Beneficência in Pernambuco, Recife, Brazil., Moreira MCR; CEMO-Instituto Nacional do Câncer, Rio de Janeiro, Brazil., Teixeira GM; Clinical Hospital of Federal University of Minas Gerais, Belo Horizonte, Brazil., da Silva CC; Bone Marrow Transplant, Amaral Carvalho Foundation, Jaú, Brazil; Bone Marrow Transplant, Hospital Israelita Albert Einstein, São Paulo, Brazil., Simioni AJ; Bone Marrow Transplant, Amaral Carvalho Foundation, Jaú, Brazil; Bone Marrow Transplant, Hospital Israelita Albert Einstein, São Paulo, Brazil., Lemes RPG; Hematology Research Laboratory, Federal University of Ceara, Fortaleza, Brazil.
Jazyk: angličtina
Zdroj: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2020 May; Vol. 26 (5), pp. 1021-1024. Date of Electronic Publication: 2020 Feb 27.
DOI: 10.1016/j.bbmt.2020.01.030
Abstrakt: It has been suggested that bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) can be valuable in the treatment of patients with myelodysplastic syndromes (MDS). However, the influence of this approach on HSCT outcomes remains poorly defined. Therefore, our objective was to investigate the influence of treatment before HSCT in patients with MDS. We retrospectively analyzed data from the Latin American registry of 258 patients from 17 Latin American centers who underwent HSCT from 1988 to 2019. Our data showed that there was pre-HSCT. We detected no significant difference regarding the impact on overall survival of treated and untreated patients before HSCT. Despite these data, the type of previous treatment among treated patients showed a significant difference in overall survival. Treatment with hypomethylating agents together with pre-HSCT chemotherapy seems to result in better survival of the studied population. These data correspond to the first results obtained through cooperative work between various centers in Latin America comparing the different approaches to patients and reflecting their reality and challenges. Therefore, the selection of pretransplant bridge therapy should be analyzed and focus given primarily to those approaches that result in better survival of patients with MDS.
(Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: